LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

Home・Akciju saraksts・CytoSorbents Corp

CytoSorbents Corp

Atvērts

SektorsVeselības aprūpe

0.76

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.75

Max

0.79

Galvenie mērījumi
By Trading Economics
Ienākumi	-5.1M -3.2M
Pārdošana	-132K 9.5M
EPS	-0.05
Peļņas marža	-33.421
Darbinieki	149
EBITDA	-5.9M -2.9M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.8M 47M
Iepriekšējā atvēršanas cena	0.76
Iepriekšējā slēgšanas cena	0.76

Ziņu noskaņojums

By Acuity

50%

128 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

0.705 / 0.771 Atbalsts un pretestība

CytoSorbents Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. marts 19:32 UTC

Iegādes, apvienošanās, pārņemšana

Diana Shipping Increases Offer to Acquire Genco -- Update

2026. g. 8. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 8. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall on Higher Energy Prices, Signs of U.S. Econ Weakness -- Market Talk

2026. g. 8. marts 23:46 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls Amid Dollar's Strength -- Market Talk

2026. g. 8. marts 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Surge Above $100/bbl Amid Growing Middle East Conflict -- Market Talk

2026. g. 8. marts 23:08 UTC

Galvenie ziņu notikumi

Front-month WTI Crude Futures Jump 16.6%, Front-Month Brent Crude Futures Climb 15.2%

2026. g. 8. marts 23:05 UTC

Galvenie ziņu notikumi

Front-month Crude Oil Futures Surge Amid Rising Middle East Conflict

2026. g. 8. marts 22:37 UTC

Galvenie ziņu notikumi

The Long-Feared Persian Gulf Oil Squeeze Is Upon -2-

2026. g. 8. marts 22:37 UTC

Galvenie ziņu notikumi

The Long-Feared Persian Gulf Oil Squeeze Is Upon Us -- WSJ

2026. g. 7. marts 02:30 UTC

Galvenie ziņu notikumi

Iran War Is Kicking India When It's Already Down -- Barrons.com

2026. g. 6. marts 22:26 UTC

Galvenie ziņu notikumi

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

2026. g. 6. marts 22:07 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

2026. g. 6. marts 22:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 6. marts 22:03 UTC

Tirgus saruna

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

2026. g. 6. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 6. marts 21:37 UTC

Peļņas

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

2026. g. 6. marts 21:25 UTC

Galvenie ziņu notikumi

How The Iran War Impacts Ukraine. -- Barrons.com

2026. g. 6. marts 21:17 UTC

Peļņas

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

2026. g. 6. marts 20:50 UTC

Peļņas

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

2026. g. 6. marts 20:46 UTC

Peļņas

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026. g. 6. marts 20:31 UTC

Galvenie ziņu notikumi

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

2026. g. 6. marts 20:18 UTC

Tirgus saruna

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

2026. g. 6. marts 20:12 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

2026. g. 6. marts 19:10 UTC

Tirgus saruna

Galvenie ziņu notikumi

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

2026. g. 6. marts 18:54 UTC

Tirgus saruna

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

2026. g. 6. marts 18:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

2026. g. 6. marts 18:08 UTC

Peļņas

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026. g. 6. marts 18:04 UTC

Peļņas

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026. g. 6. marts 18:04 UTC

Peļņas

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026. g. 6. marts 17:49 UTC

Tirgus saruna

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

Salīdzinājums

Cenas izmaiņa

CytoSorbents Corp Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytoSorbents Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.705 / 0.771Atbalsts un pretestība

All events are bearish.

Noskaņojums

By Acuity

128 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.